New combination therapy for non-Hodgkin lymphoma
Translation of a novel combination therapy approach for non-Hodgkin lymphoma
['FUNDING_U01'] · MAYO CLINIC ROCHESTER · NIH-11211672
A virus-based combination treatment aims to boost the immune system to help people and companion dogs with relapsed or treatment-resistant diffuse large B-cell lymphoma.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | MAYO CLINIC ROCHESTER (nih funded) |
| Locations | 1 site (ROCHESTER, UNITED STATES) |
| Trial ID | NIH-11211672 on ClinicalTrials.gov |
What this research studies
This work combines an engineered oncolytic virus (VSV) given intravenously with immune checkpoint drugs to try to make resistant diffuse large B-cell lymphoma more responsive to treatment. Researchers will study how the tumor microenvironment and immune cells change after treatment and monitor safety and side effects. The project uses naturally occurring lymphoma in companion dogs alongside laboratory and translational studies to mirror how the approach may work in people. Findings from the canine patients and lab analyses will guide how this combination might be used in future human treatments.
Who could benefit from this research
Good fit: Ideal candidates would be people with relapsed or refractory diffuse large B-cell lymphoma and similarly affected companion dogs that meet the trial’s health and eligibility criteria.
Not a fit: Patients with other lymphoma subtypes, early-stage disease well controlled by standard therapy, or medical conditions that prevent receiving an oncolytic virus or immunotherapy may not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could make immunotherapy work for some people with relapsed or refractory DLBCL and offer a new option when standard treatments fail.
How similar studies have performed: Checkpoint inhibitors have worked well in Hodgkin lymphoma but not reliably in NHL, and oncolytic viruses have shown promise preclinically and in early trials, so this combination is promising but still experimental.
Where this research is happening
ROCHESTER, UNITED STATES
- MAYO CLINIC ROCHESTER — ROCHESTER, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: NAIK, SHRUTHI — MAYO CLINIC ROCHESTER
- Study coordinator: NAIK, SHRUTHI
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers